Profile data is unavailable for this security.
About the company
Heartseed Inc is a Japan-based company engaged in research and development of regenerative medicine products. The Company has established cardiac regenerative medicine, a therapy in which microtissue (cardiomyocytes) derived from iPS cells are transplanted into the heart, and conducts business activities for patients with severe heart failure. Target diseases include dilated cardiomyopathy (DCM), old myocardial infarction (OMI), and dilated-phase hypertrophic cardiomyopathy (D-HCM). Except the pipeline's leading cardiac treatment HS-001 (administration of regenerated myocardium derived from allogeneic iPS cells to the myocardium), the Company also conducts research into the creation of myocardium using autologous iPS cells that do not pose immune rejection reactions and iPS cells with HLA knockout.
- Revenue in JPY (TTM)--
- Net income in JPY--
- Incorporated2015
- Employees39.00
- LocationHeartseed Inc5F, Seavans South Bldg., 1-2-3, ShibauraMINATO-KU 105-0023JapanJPN
- Phone+81 363801068
- Websitehttps://heartseed.jp/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TOT Biopharm International Co Ltd | 20.04bn | 184.65m | 28.83bn | 551.00 | 146.54 | 1.93 | 22.05 | 1.44 | 0.0136 | 0.0136 | 1.47 | 1.03 | 0.6899 | 2.44 | 6.35 | 1,940,461.00 | 0.6356 | -20.01 | 0.8392 | -25.21 | 72.02 | 74.74 | 0.9212 | -68.53 | 1.63 | 2.98 | 0.3465 | -- | 76.54 | 81.88 | 24.36 | -- | 21.04 | -- |
| CARsgen Therapeutics Holdings Ltd | 130.59m | -14.31bn | 34.82bn | 477.00 | -- | 1.14 | -- | 266.67 | -1.37 | -1.37 | 0.0125 | 2.86 | 0.0027 | -- | 0.3317 | 13,499.20 | -29.27 | -- | -32.86 | -- | 25.50 | -- | -10,960.25 | -- | 9.44 | -- | 0.1246 | -- | -- | -- | 16.19 | -- | -- | -- |
| Heartseed Inc | -100.00bn | -100.00bn | 36.41bn | 39.00 | -- | 7.92 | -- | -- | -- | -- | -- | 206.81 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 17.78 | -- | 0.0019 | -- | -30.93 | -- | -4.30 | -- | -- | -- |
| CStone Pharmaceuticals | 9.40bn | -2.93bn | 37.32bn | 164.00 | -- | 3.87 | -- | 3.97 | -0.1227 | -0.1227 | 0.3934 | 0.4001 | 0.2861 | 1.33 | 2.50 | 2,180,784.00 | -8.92 | -54.76 | -16.99 | -81.68 | 70.73 | -- | -31.17 | -301.62 | 1.45 | -- | 0.4171 | -- | -3.64 | -- | 59.32 | -- | 52.42 | -- |
| Laekna Inc | 0.00 | -6.09bn | 37.52bn | 92.00 | -- | 2.69 | -- | -- | -0.9112 | -0.9112 | 0.00 | 1.90 | 0.00 | -- | -- | 0.00 | -31.46 | -- | -35.71 | -- | -- | -- | -- | -- | -- | -- | 0.0856 | -- | -- | -- | 52.81 | -- | -- | -- |
| Abbisko Cayman Ltd | 10.24bn | -333.68m | 40.40bn | 275.00 | -- | 0.9379 | 593.35 | 3.94 | -0.0302 | -0.0302 | 0.8412 | 3.35 | 0.2159 | -- | -- | 2,117,598.00 | -0.7034 | -- | -0.733 | -- | 100.00 | -- | -3.26 | -- | -- | -- | 0.0142 | -- | -- | -- | 12.92 | -- | -- | -- |
